Inhibition of nuclear import suppresses androgen receptor action and overcomes resistance in prostate cancer (2026)

Peer-Reviewed Study · Wang X; Xu X; Fang S; Shi X; Yang Y; et al. · February 2026

Wang X et al., 2026-02: Prostate cancer study using importazole and ivermectin as nuclear-import inhibitors to show that blocking importin-mediated AR nuclear translocation suppresses AR signalling and restores enzalutamide sensitivity, including in AR-mutant and AR-V7 models.

Both importazole and ivermectin attenuated the transcriptional activation induced by a consti

n/a (HTML full text)

Wang X et al., 2026-02: Prostate cancer study using importazole and ivermectin as nuclear-import inhibitors to show that blocking importin-mediated AR nuclear translocation suppresses AR signalling and restores enzalutamide sensitivity, including in AR-mutant and AR-V7 models. Study type: prostate cancer cell models (wild-type AR, AR-F876L, AR-V7). N: n/a. Country: China (China Regional Research Center, ICGEB). Dose: not stated in the abstract. Declared COI: 'The authors declare no competing interests.' Comparator: importazole, KPNB1 knockdown, enzalutamide alone. Excerpt ends mid-sentence; the quoted words are continuous. Study type: lab.